Sensorion ended development of its OTOF-related hearing loss gene therapy program, citing a strategic review that found the development environment had “notably changed.” The decision follows competitive pressure from Regeneron’s advances in the same area. Sensorion also shifted focus within its hearing loss portfolio, selecting SENS-601 as its lead program for GJB2-related hearing loss and filing clinical trial applications for the AAV-based therapy. For developers in inner-ear gene therapy, the moves reflect the intensifying need to differentiate not only science, but also timelines, vector delivery strategies, and cohort-defining biomarker plans.